Evidence map›Paper›PMID 25992380›Full record

ReviewAnnals of translational medicine2015

Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents.

Raffaele Califano, Floriana Morgillo, Ramon Andrade De Mello, Giannis Mountzios

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Comparison ofOncotarget · 2021
    Article
  5. Review
  6. Review
  7. Article
  8. Long noncoding RNA ENST00000434223 suppressed tumor progression in non-small cell lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  9. Article
  10. Review
  11. Review
  12. Lung cancer biomarkers, targeted therapies and clinical assays.Translational lung cancer research · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Raffaele Califano1 Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK ; 2 Department of Medical Oncology, University Hospital of South Manchester NHS Foundation Trust, Manchester M23 9LT, UK ; 3 Dipartimento di internistica clinica e sperimentale "F. Magrassi e A. Lanzara", Seconda Università degli studi di Napoli, Naples, Italy ; 4 Department of Biomedical Sciences and Medicine, University of Algarve, Faro 8005-139, Portugal ; 5 Department of Medical Oncology, Portuguese Oncology Institute, Porto 4200-072, Portugal ; 6 University of Athens School of Medicine, Athens, Greece.
Floriana Morgillo1 Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK ; 2 Department of Medical Oncology, University Hospital of South Manchester NHS Foundation Trust, Manchester M23 9LT, UK ; 3 Dipartimento di internistica clinica e sperimentale "F. Magrassi e A. Lanzara", Seconda Università degli studi di Napoli, Naples, Italy ; 4 Department of Biomedical Sciences and Medicine, University of Algarve, Faro 8005-139, Portugal ; 5 Department of Medical Oncology, Portuguese Oncology Institute, Porto 4200-072, Portugal ; 6 University of Athens School of Medicine, Athens, Greece.
Ramon Andrade De Mello1 Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK ; 2 Department of Medical Oncology, University Hospital of South Manchester NHS Foundation Trust, Manchester M23 9LT, UK ; 3 Dipartimento di internistica clinica e sperimentale "F. Magrassi e A. Lanzara", Seconda Università degli studi di Napoli, Naples, Italy ; 4 Department of Biomedical Sciences and Medicine, University of Algarve, Faro 8005-139, Portugal ; 5 Department of Medical Oncology, Portuguese Oncology Institute, Porto 4200-072, Portugal ; 6 University of Athens School of Medicine, Athens, Greece.
Giannis Mountzios1 Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M20 4BX, UK ; 2 Department of Medical Oncology, University Hospital of South Manchester NHS Foundation Trust, Manchester M23 9LT, UK ; 3 Dipartimento di internistica clinica e sperimentale "F. Magrassi e A. Lanzara", Seconda Università degli studi di Napoli, Naples, Italy ; 4 Department of Biomedical Sciences and Medicine, University of Algarve, Faro 8005-139, Portugal ; 5 Department of Medical Oncology, Portuguese Oncology Institute, Porto 4200-072, Portugal ; 6 University of Athens School of Medicine, Athens, Greece.
Manchester University NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

All patients with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC) treated with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) such as gefitinib, erlotinib or afatinib will progress after a median of 9-12 months. So far, development of a secondary T790M mutation represents the most common (approximately 60%) mechanism of resistance to these drugs. The relative rarity of mesenchymal-epithelial transition (MET) amplification in NSCLC suggests that this event plays a limited role in primary resistance to EGFR-TKI. In contrast, MET gene amplification has been detected as a secondary event representing one of the most relevant mechanisms involved in the acquired resistance to EGFR-TKIs both in preclinical and clinical studies. The aim of this review is to discuss the role of MET amplification as a mechanism of resistance to anti-EGFR therapies and to review strategies which aim at overcoming this mechanism of resistance, including studies assessing drug combinations targeting both EGFR and MET pathways.

Indexed as

crizotinibEpidermal growth factor receptor (EGFR)mesenchymal-epithelial transition (MET)onartuzumabtivantinib

Identifiers

PMID25992380
PMCPMC4416951
OpenAlexW321828952

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.